Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesKi67 expression and docetaxel efficacy in patients with estrogen receptor–positive breast cancer
Journal of Clinical Oncology, 06/10/09
Penault-Llorca F et al. - In a study to analyze the predictive value of Ki67, HER2, and progesterone receptor (PR) expression for the efficacy of docetaxel in pts with ER-positive, node-positive breast cancer, it was concluded that Ki67 expression identifies a subset of pts with ER-positive breast cancer who could be sensitive to docetaxel treatment in the adjuvant setting.
Methods- Expression of Ki67, HER2, and PR was measured by immunohistochemistry in tumor samples from 798 pts with ER-positive breast cancer.
- Risk reduction was evaluated using a Cox model adjusted for age, tumor size, nodal involvement, treatment arm, and biomarkers.
- Predictive value of biomarkers was assessed by an interaction test.
- Disease-free survival (DFS) was the primary endpoint.
- Ki67, HER2, and PR were expressed in 21%, 9%, and 62% of samples, respectively.
- Hazard ratios for relapse associated with docetaxel were 0.51 in ER-positive/Ki67-positive tumors and 1.03 in ER-positive/Ki67-negative tumors.
- 5-yr DFS rates were 81% and 84% in pts with ER-positive/Ki67-negative and ER-positive/Ki67-positive tumors treated with docetaxel and 81% and 62% in pts with ER-positive/Ki67-negative and ER-positive/Ki67-positive tumors treated with fluorouracil, epirubicin, and cisplatin.
- No trend for interaction was observed between docetaxel and HER2, nor between docetaxel and PR.
Related Articles
Systematic Review: Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer
Annals of Internal Medicine, 11/19/09
Relevance Score: 94%%
Gli1 promotes cell survival and is predictive of a poor outcome in ER &alpha-Negative breast cancer
Breast Cancer Research and Treatment, 11/17/09
Relevance Score: 94%%
GPR30 and estrogen receptor expression: New insights into hormone dependence of inflammatory breast cancer
Breast Cancer Research and Treatment, 11/16/09
Relevance Score: 93%%
Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance
Breast Cancer Research and Treatment, 11/04/09
Relevance Score: 93%%
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Breast Cancer Research, 11/04/09
Relevance Score: 93%%
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Development and characterization of a novel method for the analysis of gene expression patterns in lymphatic endothelial cells derived from primary breast tissues
Journal of Cancer Research & Clinical Oncology, 12/03/09
Microglandular adenosis or microglandular adenoma? A molecular genetic analysis of a case associated with atypia and invasive carcinoma
Histopathology, 12/03/09
Histological grading of invasive breast carcinoma a simplification of existing methods in a large conservation series with long-term follow-up
Histopathology, 12/03/09
Sponsor
Article Search
Sponsor
Sponsor